They've had significant fluctuations in profitability in the past few years:
NPAT
2019: $13m
2020: $16m
2021: $47m
2022: $41m
Not sure how much they were a lockdown beneficiary given that seeming correlation and without guidance it's hard to forecast 2023.
But at trailing 7x NPAT with a 14% gross dividend if they can match something like $40m NPAT consistantly it doesn't need to grow earnings to beat the market.
Blundy invested is huge for confidence and a major factor in believing this could be an investment with future excess returns.
- Forums
- ASX - By Stock
- BST
- Ann: FY22 Full Year Results Presentation
Ann: FY22 Full Year Results Presentation, page-7
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BST (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.88 |
Change
0.000(0.00%) |
Mkt cap ! $235.0M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
BST (ASX) Chart |
Day chart unavailable
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, MD & CEO
James Graham
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online